Market Place
Sourcing Support
Elicio Therapeutics Shares ELI-002 Results At ESMO 2024
12 Dec 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Completes Enrollment in Ph 2 Amplify-7P Study
03 Dec 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q3 2024 Results & Updates
13 Nov 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Updates Data from AMPLIFY-7P Study at SITC
07 Nov 2024 //
GLOBENEWSWIRE
Elicio Therapeutic to Present Data at SITC & SU2C Innovation Summit
31 Oct 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
16 Oct 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
17 Sep 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Three Upcoming Presentations On Vaccines
13 Sep 2024 //
GLOBENEWSWIRE
Elicio Therapeutics To Present At H.C. Wainwright Conference
28 Aug 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q2 2024 Results And Corporate Updates
13 Aug 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Closes $20M Convertible Note Private Placement
12 Aug 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Prices $11.5M Underwritten Public Offering
28 Jun 2024 //
GLOBENEWSWIRE
Elicio Announces Disease-Free Survival from the Ongoing AMPLIFY-7P Phase 1a
27 Jun 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Proposed Public Offering
27 Jun 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
18 Jun 2024 //
GLOBENEWSWIRE
Elicio Eli-002 Prelim Phase 1a: Mkras Tumors At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Q1 2024 Results, Corporate Updates
15 May 2024 //
GLOBENEWSWIRE
Elicio`s ELI-002 mKRAS Data at ASCO 2024
25 Apr 2024 //
GLOBENEWSWIRE
Elicio Therapeutics to Data on ELI-007 and ELI-008 at the AACR Annual Meeting
05 Apr 2024 //
GLOBENEWSWIRE
Elicio Reports 2023 Financial Results and Provides Corporate Updates
29 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces $6.0 Million Private Placement Financing
18 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Upcoming Presentations at the AACR Annual Meeting
06 Mar 2024 //
GLOBENEWSWIRE
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Conference
05 Feb 2024 //
GLOBENEWSWIRE
Elicio Announces Publication of Data Demonstrating TCR-T Cell Therapy
25 Jan 2024 //
GLOBENEWSWIRE
Elicio to Present ELI-002 7P Trial in Progress Poster on Phase 1/2 Study
17 Jan 2024 //
GLOBENEWSWIRE
Elicio to Present at the B. Riley Securities 4th Annual Oncology Conference
16 Jan 2024 //
GLOBENEWSWIRE
Elicio Announces First Patient Dosed in Phase 2 Pancreatic Cancer Study
11 Jan 2024 //
GLOBENEWSWIRE
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
09 Jan 2024 //
PRESS RELEASE
Nature Medicine Publishes Updated Phase 1 Data From Elicio`s Study of ELI-002
09 Jan 2024 //
GLOBENEWSWIRE
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
22 Dec 2023 //
GLOBENEWSWIRE
Elicio Therapeutics to Present at H.C. 4th Annual Precision Oncology Conference
04 Dec 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Presents Data from the Ongoing Phase 1 Study of ELI-002
03 Nov 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Upcoming Presentations at SITC
11 Oct 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Presents Survival Data from the Phase 1 Study of ELI-002
27 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Receives $2.6 Million Grant from the GI Research Foundation
07 Sep 2023 //
GLOBENEWSWIRE
Elicio to Present at H.C. Wainwright 25th Annual Global Investment Conference
06 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002
05 Sep 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grants
22 Aug 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Completes Reverse Merger and Provides a Corporate Update
06 Jun 2023 //
GLOBENEWSWIRE
Elicio Announces Positive Interim Data from the Phase 1 Study of ELI-002
03 Jun 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Reports Inducement Grant to New Chief Financial Officer
02 Jun 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Completion of Merger with Angion Biomedica
01 Jun 2023 //
GLOBENEWSWIRE
Elicio to Present Interim Data from the Ongoing Phase 1 Study of ELI-002
01 May 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Announces First Patient Dosed in Phase 1/2 Study
27 Apr 2023 //
GLOBENEWSWIRE
Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica
17 Jan 2023 //
BIOSPACE
Cancer vaccine developer jumps to Nasdaq via reverse merger
17 Jan 2023 //
ENDPTS
Elicio Therapeutics Announces Publication of Preclinical Data in Science
04 Oct 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Receives $2.8 Million Grant from the (GIRF)
20 Sep 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Announces Publication of Preclinical Data on ELI-005
07 Sep 2022 //
GLOBENEWSWIRE
Elicio`s PC Data on Lymph Node-Targeted SARS-CoV-2 Amphiphile Vaccine, ELI-005
06 Jul 2022 //
GLOBENEWSWIRE
Elicio Tx Presents PC Data on AMP-CpG Adjuvant in Combination with EBV Vaccine
06 Jul 2022 //
GLOBENEWSWIRE
Elicio Shows Design of Ongoing AMPLIFY-201 Study in Mutant KRAS-Driven Cancers
27 May 2022 //
GLOBENEWSWIRE
Elicio Announces Publication of Preclinical Data Showing AMP-Peptide Vaccine
23 May 2022 //
GLOBENEWSWIRE
Elicio Therapeutics Enters Clinical Supply Agreement with Regeneron
16 May 2022 //
CONTRACTPHARMA
Elicio Appoints Joy Seymour as VP, Head of RA and Dr. Peter DeMuth to CSO
12 May 2022 //
GLOBENEWSWIRE
Elicio Presents Preclinical Data on the AMP-Peptide Vaccine + TCR-T Cell Therapy
29 Apr 2022 //
GLOBENEWSWIRE
Elicio Tx Presents Updated PC Data at Vaccines Summit Boston 2022 on ELI-005
29 Mar 2022 //
GLOBENEWSWIRE
